Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study

BACKGROUND: The United States Preventive Services Task Force supports individualised decision-making for prostate-specific antigen (PSA)-based screening in men aged 55–69. Knowing how the potential benefits and harms of screening vary by an individual’s risk of developing prostate cancer could infor...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:PLoS Med
Main Authors: Callender, Tom, Emberton, Mark, Morris, Steve, Eeles, Ros, Kote-Jarai, Zsofia, Pharoah, Paul D. P., Pashayan, Nora
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2019
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6924639/
https://ncbi.nlm.nih.gov/pubmed/31860675
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1002998
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki